Successful Proof-of-Concept for Topical Delivery of Novel Peptide ALM201 with Potential Usefulness for Treating Neovascular Eye Disorders.

Obasanmi, Gideon; Nesbit, M Andrew; Cobice, Diego; Mackay, Logan; McGimpsey, Stuart; Wappett, Mark; Cranston, Aaron N; Moore, Tara C B.

Afiliação

Obasanmi G; Biomedical Sciences Research Institute, School of Biomedical Sciences, Ulster University, Coleraine, United Kingdom.
Nesbit MA; Biomedical Sciences Research Institute, School of Biomedical Sciences, Ulster University, Coleraine, United Kingdom.
Cobice D; Biomedical Sciences Research Institute, School of Biomedical Sciences, Ulster University, Coleraine, United Kingdom.
Mackay L; Scottish Instrumentation and Research Centre for Advanced Mass Spectrometry (SIRCAMS), School of Chemistry, University of Edinburgh, Edinburgh, United Kingdom.
McGimpsey S; Mater Infirmorum Hospital (Belfast Health and Social Care Trust), Belfast, United Kingdom.
Wappett M; Centre for Precision Therapeutics, Almac Discovery Ltd., Belfast, United Kingdom.
Cranston AN; Centre for Precision Therapeutics, Almac Discovery Ltd., Belfast, United Kingdom.
Moore TCB; Biomedical Sciences Research Institute, School of Biomedical Sciences, Ulster University, Coleraine, United Kingdom.

Ophthalmol Sci ; 2(2): 100150, 2022 Jun.

Article em En | MEDLINE | ID: mdl-36249680

Palavras-chave

AMD, age-related macular degeneration; Age-related macular degeneration; Angiogenesis; CNV, choroidal neovascularization; CV, corneal vascularization; Choroidal neovascularization; Corneal vascularization; HRA, Heidelberg retinal angiograph; Ocular neovascularization; PBS, phosphate-buffered saline; ROI, region of interest; VEGF, vascular endothelial growth factor; nAMD, neovascular age-related macular degeneration

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article